Serious Renal Impairment Occurs Rarely with Use of Tenofovir DF

REFERENCES

• Staszewski S, Gallant JE, Pozniak AL, et al. Three-year analysis of the renal safety of tenofovir DF (TDF) versus stavudine (d4T) when used in combination with lamivudine (3TC) and efavrienz (EFV) and anti-retroviral naive patients. Presented at the XV International AIDS Conference; 2004; Bangkok, Thailand.
   Google Scholar
• Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients. JAMA. 2004;292(2):191–201.
   PubMed Web of Science ®Google Scholar
• Lee JC, Marosok RD. Acute tubular necrosis in a patient receiving tenofovir. AIDS. 2003;17:2543–2544.
   PubMed Web of Science ®Google Scholar
• Peyriere H, Reyenes J, Rouanet I, et al. Renal tubular dys-function associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr. 2004;35:269–273.
   PubMed Web of Science ®Google Scholar
• Schaaf B, Aries P, Kramme E, Steinhoff J, Dalhoff K. Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome. Clin Infect Dis. 2003;37:e41–43.
   PubMed Web of Science ®Google Scholar
• Zimmerman AE, Pizzoferrato T, Bedford J, Morris AB, Hoffman R, Braden G. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis. 2006;42(2):283–290.
   PubMed Web of Science ®Google Scholar
• DuPont C, Meier F, Loupy A, Page B, Rouvieix E. Acute renal failure and tenofovir: 2 new cases. In: Program and abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treat-ment; July 13–16, 2003; Paris, France. Abstract 694.
   Google Scholar
• Creput C, Gonzalez-Canali G, Hill G, Piketty C, Kazatchkine M, Nochy D. Renal lesions in HIV-1-positive patient treated with tenofovir. AIDS. 2003;17(6):935–937.
   PubMed Web of Science ®Google Scholar
• Coca S, Perazella MA. Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci. 2002;324(6):342–344.
   PubMed Web of Science ®Google Scholar
• Gaspar G, Monereo A, Garcia-Reyne A, Guzman M. Fanconi syndrome and acute renal failure in a patient treated with tenofovir: a call for caution. AIDS. 2004;18(3):351–352.
   PubMed Web of Science ®Google Scholar
• Rollot F, Nazal E, Chauvelot-Moachon L, et al. Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipi-dus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine. Clin Infect Dis. 2003;37:e174–176.
   PubMed Web of Science ®Google Scholar
• Karras A, Lafaurie M, Furco A, et al. Tenofovir-related neph-rotoxicity in human immunodeficiency virus-infected pa-tients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis. 2003;36(8)1070–1073.
   Web of Science ®Google Scholar
• Verhelst D, Monge M, Meynard J, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis. 2002;40(6)1331–1333.
   Web of Science ®Google Scholar
• Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.
   PubMed Web of Science ®Google Scholar
• Scott JD, Wolfe PR, Quiros J, Behrooznia E, Guyer B, Bolan RK. Rare occurrence of renal toxicity when retrospectively evaluating the use of tenofovir DF in 2 clinical practices. In: Program and abstracts of the International AIDS Confer-ence; 2004; Bangkok, Thailand. Abstract TuPeB4632.
   Google Scholar
• Scott JD, Wolfe PR, Chow J, Guyer B, Bolan RK. Rare occurrence of renal toxicity when retrospectively evaluating the use of tenofovir DF in 2 clinical practices. Presented at: ASHP-Midyear Clinical Meeting; 2003; New Orleans. P–448E.
   Google Scholar
• Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected pa-tients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2005;40:1559–1585.
   PubMed Web of Science ®Google Scholar
• Gupta SK, Mamlin BW, Johnson CS, Dollins MD, Topf JM, Dube MP. Prevalence of proteinuria and the development of chronic kidney disease in HIV-infected patients. Clin NephroL 2004;61(1):1–6.
   PubMed Web of Science ®Google Scholar
• Cihlar T, Ho ES, Lin DC, Mulato AS. Human Renal Organic Anion Transporter 1 (hOAT1) and its role in the nephrotoxic-ity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids. 2001 ;20(4-7):641–648.
   PubMed Web of Science ®Google Scholar
• Jones R, Stebbing J, Nelson M, et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more fre-quently: a cohort and case-control study. J Acquir Immune Defic Syndr. 2004;37(4):1489–1495.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function in patients treated with tenofovir DF com-pared to nucleoside reverse transcriptase inhibitors. Pre-sented at: 12th Conference on Retroviruses and Opportu-nistic Infections; February 22–25, 2005; Boston, MA.
   Google Scholar
• Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fuma-rate treatment, compared to nucleoside reverse-tran-scriptase inhibitor treatment. Clin Infect Dis. 2005;40:1194–1198.
   PubMed Web of Science ®Google Scholar
• Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461–470.
   Web of Science ®Google Scholar
• Scott JD, Shibuyama S, Anderson D, Bolan RK. Rare occurence of renal impairment when retrospectively evaluating the use of tenofovir DF when used >12 months. In: Program and abstracts of the 10th European AIDS Conference; November 17–20, 2005; Dublin, Ire-land. Abstract 9.1/2.
   Google Scholar